Department of Hematology, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan.
Int J Hematol. 2012 Mar;95(3):291-8. doi: 10.1007/s12185-012-1009-x.
We retrospectively analyzed patients aged C 50 years with hematologic malignancies who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) to identify preoperative variables predicting the outcome. There were 71 patients with a median age of 57 years (range: 50-63 years) who had acute leukemia (n = 53) or myelodysplastic syndrome (n = 18). Myeloablative conditioning was done in 35 patients and 36 patients had reduced-intensity conditioning. The 5-year overall survival rate (OS), cumulative relapse rate, and non-relapse mortality rate (NRM) were 45, 24, and 33%, respectively. According to multivariate analysis, high-risk disease (HR 3.50, 95% CI 1.43-8.56, P = 0.006), a hematopoietic cell transplantation comorbidity index (HCT-CI) score ≥ 3 (HR 4.41, 95% CI 1.31-14.77, P = 0.016), and an HLA-mismatched unrelated donor (HR 4.03, 95% CI 1.46-11.10, P = 0.007) were significant predictors of worse OS. Highrisk disease was also significantly associated with a higher cumulative relapse rate (HR 4.59, 95% CI 0.94-6.92, P = 0.065). Furthermore, an HCT-CI score ≥ 3 (HR 3.02, 95% CI 1.01-20.78, P = 0.048) and an HLA-mismatched unrelated donor (HR 3.02, 95% CI 1.04-8.74, P = 0.042) were risk factors for NRM. These results suggest that the disease risk, HCT-CI score, and donor type/histocompatibility are prognostic factors for elderly patients, while the conditioning regimen and age are not predictors.
我们回顾性分析了年龄在 50 岁以上的接受异基因造血干细胞移植(allo-HSCT)的血液恶性肿瘤患者,以确定预测结局的术前变量。共有 71 例中位年龄为 57 岁(范围:50-63 岁)的患者,其中急性白血病(n=53)或骨髓增生异常综合征(n=18)。35 例患者接受了清髓性预处理,36 例患者接受了强度降低预处理。5 年总生存率(OS)、累积复发率和非复发死亡率(NRM)分别为 45%、24%和 33%。根据多变量分析,高危疾病(HR 3.50,95%CI 1.43-8.56,P=0.006)、造血细胞移植合并症指数(HCT-CI)评分≥3(HR 4.41,95%CI 1.31-14.77,P=0.016)和 HLA 不匹配的无关供体(HR 4.03,95%CI 1.46-11.10,P=0.007)是 OS 较差的显著预测因素。高危疾病也与更高的累积复发率显著相关(HR 4.59,95%CI 0.94-6.92,P=0.065)。此外,HCT-CI 评分≥3(HR 3.02,95%CI 1.01-20.78,P=0.048)和 HLA 不匹配的无关供体(HR 3.02,95%CI 1.04-8.74,P=0.042)是 NRM 的危险因素。这些结果表明,疾病风险、HCT-CI 评分和供体类型/组织相容性是老年患者的预后因素,而预处理方案和年龄不是预测因素。